Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
The tale of two global HIV responses continues to unfold this week, in data released by UNAIDS in the run-up to the 22nd International AIDS Conference […]
Advocates hail South Africa bedaquiline recommendation, replacing toxic injection for patients with drug-resistant tuberculosis
Medicine represents third choice over “deaf or dead” for many patients, health worker/tuberculosis survivor-founded organization says Praising the treatment policy decision of South Africa health officials […]
Tools to diagnose and monitor HIV, hepatitis B and C, and tuberculosis, as well as resistance to first-line TB treatment are among the tests included in […]
The following is a guest post by By Jackie Hellen, MPH of MEASURE Evaluation Community workers and program managers work tirelessly to control HIV at the local […]